Abingdon Health

Abingdon Health, a leading international developer and manufacturer of high quality and effective rapid tests, is delighted to announce its lateral flow test (LFT) contract services and product sales team will be exhibiting at Medica 2022.

Abingdon Health plc, a leading international developer and manufacturer of high quality and effective rapid tests, recently announced the launch of a new self-test e-commerce website, Abingdon Simply Test.

Abingdon Health plc, a leading international developer and manufacturer of high quality and effective rapid tests, announces the commercial launch and UKCA and CE-marking of AbC-19™ Semi-Q Rapid Test.

York based rapid test developer and manufacturer, Abingdon Health, announces its membership of the UK Rapid Test Consortium. A consortium formed in response to UK Government's request to increase COVID-19 testing.

Abingdon Health and DCN Diagnostics have announced a commercial partnership to provide Abingdon Health's proprietary AppDx Smartphone m-Health technology to DCN Diagnostics' customer base.

In situations such as the coronavirus outbreak there is a potential for rapid test supply to fall behind demand. This is where a second manufacturer can address this issue.

Following a successful 2019, Abingdon Health is expanding its York-based facility, giving the company the space and capabilities necessary to continue to drive forward rapid diagnostic testing innovation and growth.

In a recent CCLM publication, the authors concluded that Seralite® FLC Serum, a quantitative lateral flow immunoassay, has shown good clinical concordance when compared with other sFLC assays.

Octylphenol ethoxylates (OPE) are now in the Annex XIV of REACH. Why do OPEs feature in this list and what does it mean for lateral flow rapid tests that use OPEs, such as Triton-X?

'85% of all clinical trials fail to recruit enough patients and 80% are delayed due to recruitment problems and dropout rates are high' (Source: biopharmadive.com).